![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 18, 15607-15612, May 3, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the § Division of Infectious Diseases,
Childrens Hospital Los Angeles, University of Southern California
School of Medicine, Los Angeles, California 90027 and the
Received for publication, December 20, 2001, and in revised form, February 1, 2002
Escherichia coli K1 invasion of brain
microvascular endothelial cells (BMECs) is a prerequisite for
penetration into the central nervous system and requires actin
cytoskeletal rearrangements. Here, we demonstrate that E. coli K1 invasion of BMECs requires RhoA activation. In addition,
we show that cytotoxic necrotizing factor-1 (CNF1) contributes to
E. coli K1 invasion of brain endothelial cells in
vitro and traversal of the blood-brain barrier in the experimental hematogenous meningitis animal model. These in
vitro and in vivo effects of CNF1 were dependent upon
RhoA activation as shown by (a) decreased invasion and RhoA
activation with the Inadequate knowledge of the pathogenesis associated with bacterial
entry into the central nervous system contributes to considerable mortality and morbidity associated with bacterial meningitis. For
example, most cases of bacterial meningitis occur as a result of
hematogenous spread, but it is unclear how circulating bacteria cross
the blood-brain barrier (1). Escherichia coli is the most
common Gram-negative microorganism causing meningitis in the neonatal
period. We have previously shown that E. coli K1 crossing of
the blood-brain barrier in vivo requires a threshold level
of bacteremia and invasion of brain microvascular endothelial cells
(BMECs)1 and identified
several E. coli determinants (OmpA, Ibe proteins, AslA, and
TraJ) contributing to BMEC invasion in vitro and in vivo (2-7). We have also demonstrated that host cell actin
cytoskeletal rearrangements are required for E. coli K1
invasion of BMECs, as shown by invasive E. coli
K1-associated F-actin condensation and blockade of E. coli
K1 invasion of BMECs by the microfilament-disrupting agents
cytochalasin D and latrunculin A (8); but the specific host cell
signaling pathways involved in E. coli K1 invasion and actin
cytoskeletal rearrangements remain incompletely understood.
Our recent studies have shown that tyrosine phosphorylation of several
host cell signaling molecules is involved in E. coli K1
invasion of BMECs, as treatment of BMECs with genistein, a protein-tyrosine kinase inhibitor, blocks E. coli K1
invasion of BMECs (9). In addition, focal adhesion kinase (FAK) and phosphatidylinositol 3-kinase (PI3K) are crucial signaling pathways contributing to E. coli K1 invasion of BMECs (9, 10), but the basis of E. coli K1 activation of FAK and PI3K has yet
to be defined. It is also unclear which microbial factors contribute to
actin cytoskeletal rearrangements in BMECs.
Cytotoxic necrotizing factor-1 (CNF1) is a dermonecrotic protein toxin
produced by human and animal isolates of E. coli. CNF1 consists of 1014 amino acids with a molecular mass of 113.7 kDa. CNF1
is frequently associated with E. coli strains that cause extraintestinal infections in humans (11, 12). However, the exact role
of CNF1 in the pathogenesis of extraintestinal E. coli infections is not fully understood. Previous studies have indicated that CNF1 induces phagocytosis in epithelial cells (13-15). CNF1 has
been shown to activate Rho GTPases by deamidation of glutamine 63, converting it into glutamic acid, thereby inhibiting GTP-hydrolyzing activity and constitutive activation of Rho, resulting in
polymerization of F-actin and increased formation of stress fibers
(16-18). In this study, we examined the role of CNF1 in E. coli K1 invasion of BMECs in vitro and traversal of the
blood-brain barrier in the experimental hematogenous meningitis animal
model and the mechanisms associated with CNF1 in E. coli K1
invasion of BMECs.
Bacterial Strains and Culture Conditions--
E. coli
K1 strain E44 is a spontaneous rifampin-resistant mutant of strain
RS218 (O18:K1:H7), a cerebrospinal fluid isolate from a neonate with
meningitis (4). E. coli K12 strain JM101 (New England
Biolabs Inc., Beverly, MA) was used as the host for plasmids, and SM10
Construction of the cnf1 Deletion Mutant--
Oligonucleotide
primers were designed based on the published sequence of the
cnf1 gene (20). A 1-kb DNA fragment was obtained using
primers 5'-GGCAGCCATTTGATTTTG-3' and 5'-TTCCGCTTGTAATGATTAC-3' and
cloned into pBluescript KS (Stratagene, La Jolla, CA). A 0.9-kb DNA
fragment upstream of cnf1 was produced using primers
5'-ACGGATCCCGCGACGGAAGCT-3', incorporating a
BamHI site (underlined), and
5'-AAGAATTCTTAATGTAATCGCT-3', incorporating an
EcoRI site (underlined), and cloned into the above-mentioned
plasmid; and then a kanamycin resistance cassette from pUC4K
(Amersham Biosciences) was inserted at the EcoRI site. The
recombinant DNA was moved to suicide plasmid pET185.2 and then
transferred to strain E44 by conjugation. The cnf1 deletion mutant was selected on kanamycin and verified by PCR.
Purification of CNF1--
The cnf1 gene was amplified
from E. coli K1 strain E44 using oligonucleotide primers
5'-ACGGATCCCGCGACGGAAGCT-3', incorporating a
BamHI site (underlined), and
5'-ACGAATTCTCATTTGTTTGCCTT-3', incorporating an
EcoRI site (underlined), and cloned into pBluescript KS at
the same sites to produce pB-cnf1. CNF1 was expressed in E. coli JM101 and purified using published protocols
(14).
Endothelial Cell Cultures and Transfections--
Human BMECs
were isolated and cultured as previously described (21). BMEC cultures
were grown in RPMI 1640 medium containing 10% heat-inactivated fetal
bovine serum, 10% NuSerum, 2 mM glutamine, 1 mM pyruvate, 100 units/ml penicillin, 100 µg/ml
streptomycin, essential amino acids, and vitamins. PI3K mutants In Vitro Human BMEC Invasion Assays--
Invasion assays were
performed as previously described (4, 9). Confluent cultures of human
BMECs (grown in 24-well plates) were incubated with 107
E. coli cells (multiplicity of infection of 100) in
experimental medium (Medium 199/Ham's F-12 medium (1:1) containing 5%
heat-inactivated fetal bovine serum, 2 mM glutamine, and 1 mM pyruvate). Plates were incubated at 37 °C in a 5%
CO2 incubator for 90 min. Monolayers were washed with RPMI
1640 medium and incubated with experimental medium containing
gentamicin (100 µg/ml) for 1 h to kill extracellular bacteria.
The monolayers were washed again and lysed in 0.5% Triton X-100. The
released intracellular bacteria were enumerated by plating on sheep
blood agar plates. To examine the role of RhoA in E. coli
invasion of human BMECs, cells were treated with the Rho kinase
inhibitor Y-27632 (Calbiochem) (24), and invasion assays were
performed. To determine the effects of CNF1 on E. coli K1
invasion, monolayers were incubated with CNF1 in experimental medium
for 2 h before addition of the bacteria.
Rat Model of E. coli K1 Meningitis--
The cnf1
deletion mutant was examined for its ability to enter the central
nervous system using our neonatal rat model of hematogenous E. coli meningitis as previously described (25). Briefly, at 5 days
of age, all members of each litter were randomly divided into two
groups to receive subcutaneously 105 colony-forming units
of E. coli K1 strain E44 or its cnf1 deletion mutant. At 18 h after bacterial inoculation, blood and
cerebrospinal fluid specimens were obtained for quantitative cultures.
The development of meningitis was defined as positive cerebrospinal
fluid cultures. All experiments were performed in compliance with
National Institutes of Health and institutional guidelines.
Immunofluorescence Assays for Determination of Stress Fiber
Formation--
Human BMECs were stimulated with CNF1 for 2 h and
fixed with 4% paraformaldehyde in phosphate-buffered saline for 15 min
at room temperature. Following fixation, cells were permeabilized with
0.3% saponin in phosphate-buffered saline for 30 min at room temperature. Finally, cells were incubated with rabbit polyclonal antibody against actin (Sigma) for 60 min at room temperature, followed
by incubation with TRITC-labeled anti-rabbit antibody for 60 min at
room temperature, and visualized under an immunofluorescence microscope (8).
Western Blotting for Detection of GTP-RhoA--
Human BMECs were
lysed in radioimmune precipitation assay buffer (50 mM
Tris-HCl (pH 7.4), 0.1% SDS, 0.5% sodium deoxycholate, 10 mM sodium pyrophosphate, 25 mM
An equal amount of protein (500 µg to 1 mg) was incubated with
glutathione S-transferase-rhotekin (Upstate
Biotechnologies, Inc., Lake Placid, NY) for 45 min at 4 °C to
collect active forms of RhoA, i.e. GTP-RhoA. The protein
complex was washed with radioimmune precipitation assay buffer,
resolved by 10% SDS-PAGE, and transferred to nitrocellulose membrane.
The blots were blocked with 25 mM Tris (pH 7.4), 150 mM NaCl, and 0.1% Tween 20 containing 4% skim milk for 60 min at 22 °C. After blocking, the membranes were incubated overnight
at 4 °C with mouse monoclonal antibody against RhoA (Santa Cruz
Biotechnology, Santa Cruz, CA) and subsequently incubated for 60 min at
22 °C with horseradish peroxidase-linked secondary antibody against
mouse. Antibody-bound RhoA was visualized using an enhanced
chemiluminescence kit (Amersham Biosciences) (26). A single band of
RhoA in the 21-kDa range was detected.
The cnf1 Deletion Mutant of E. coli K1 Is Less Efficient in
Invasion of Human BMECs in Vitro and Penetration of the Blood-Brain
Barrier in the Hematogenous Meningitis Model in Vivo--
To determine
whether CNF1 plays a role in E. coli K1 invasion of BMECs,
an isogenic E44 mutant ( Requirement of RhoA in E. coli K1 Invasion of Human BMECs--
To
determine the role of RhoA in E. coli K1 invasion of human
BMECs, monolayers were treated with Y-27632 (a Rho kinase inhibitor), and invasion assays were performed. Y-27632 exhibited a
dose-dependent inhibition of E. coli K1 invasion
of human BMECs (Fig. 4), suggesting that
RhoA plays a role in E. coli K1 invasion of human BMECs. To
further confirm these findings, invasion assays were performed using
BMECs expressing dominant-negative RhoA ( The cnf1 Deletion Mutant Is Less Efficient in RhoA
Activation--
Rho GTPases, shown to affect actin cytoskeletal
rearrangements, are the target of CNF1 (13, 16, 17). To assess whether the cnf1 deletion mutant lacks the ability of RhoA
activation, human BMECs were incubated with E. coli K1
strain E44 and its cnf1 deletion mutant, and total lysates
were compared for the activated GTP form of RhoA. The cnf1
deletion mutant was significantly less efficient in activation of RhoA
GTPase compared with parent strain E44 (p < 0.05)
(Fig. 6, a and b).
Of interest, the cnf1 deletion mutant of E44 exhibited
increased RhoA activation compared with the negative control
(laboratory E. coli strain HB101) (Fig. 6, a and
b). We have previously shown that several E. coli
determinants such as OmpA, Ibe proteins, AslA, and TraJ contribute to
BMEC invasion (2-7), and it may be possible that one or more of
these microbial determinants also contribute to RhoA activation.
Overall, these findings suggest that CNF1 contributes to E. coli K1 invasion of BMECs most likely via RhoA activation. This
concept was further supported by the demonstration that the invasive
ability of the cnf1 deletion mutant was restored to the
level of the parent E. coli K1 strain in BMECs with
constitutively active RhoA (Fig. 5).
CNF1 Treatment Dramatically Increases E. coli K1 Invasion of Human
BMECs--
Next, to determine the effects of CNF1 on E. coli K1 invasion, we incubated human BMECs with purified CNF1 for
2 h prior to invasion assays. A >40-fold increase in E. coli K1 invasion of BMECs was observed in CNF1-treated cells
(Table II). We previously reported that tyrosine phosphorylations of
FAK and PI3K are essential for E. coli K1 invasion of human
BMECs, as shown by significantly decreased invasion of E. coli K1 in dominant-negative FAK- and PI3K-expressing BMECs (Table
II) (9, 10). However, CNF1-mediated E. coli K1 invasion of
human BMECs was independent of FAK and PI3K. This was shown by the
demonstration that CNF1 enhanced E. coli K1 invasion of
pcDNA-transfected BMECs as well as of both dominant-negative FAK-
and PI3K-expressing BMECs (Table II).
However, prior treatment of dominant-negative RhoA-expressing BMECs
with CNF1 resulted in a minimal increase in E. coli K1 invasion, documenting that RhoA is the major target in CNF1-mediated invasion of E. coli K1 in human BMECs. In addition, human
BMECs were treated with Y-27632 and then with CNF1, followed by the invasion assays. We observed that CNF1 did not increase invasion substantially in cells that were pretreated with Y-27632 (Table II),
thus further confirming that CNF1-mediated increased E. coli K1 invasion of human BMECs requires RhoA activation.
CNF1 Induces Stress Fiber Formation in Human BMECs--
We have
demonstrated that host cell actin cytoskeletal rearrangements are
required for E. coli K1 invasion of BMECs (8). CNF1 has been
shown to activate Rho GTPases, resulting in polymerization of F-actin
and increased formation of stress fibers in human umbilical vein
endothelial cells (18). To determine whether CNF1 induces stress fiber
formation in human BMECs, cells were incubated with CNF1 for 2 h,
and immunofluorescence assays were performed. We observed
increased stress fiber formation in CNF1-treated
pcDNA-transfected BMECs (Fig. 7).
Consistent with the above invasion data, CNF1-induced stress fiber
formation was also observed in both dominant-negative FAK- and
PI3K-expressing BMECs (Fig. 7). In contrast, CNF1 did not induce stress
fiber formation in dominant-negative RhoA-expressing BMECs (Fig. 7) and
in Y-27632-pretreated BMECs (data not shown).
CNF1-mediated Invasion and Cytoskeletal Rearrangements Are
Independent of FAK and PI3K, but Dependent on RhoA--
To verify the
activation of RhoA following CNF1 treatment, human BMECs were
stimulated with CNF1 for 30 min, and GTP-RhoA was collected as
described under "Experimental Procedures." We observed increased
levels of GTP-RhoA in response to CNF1 in pcDNA-transfected BMECs
as well as in both dominant-negative FAK- and PI3K-expressing BMECs
(Fig. 8, a and b).
CNF1 treatment of dominant-negative RhoA-expressing BMECs did not
result in RhoA activation (Fig. 8, a and b).
Taken together, these findings indicate that CNF1-mediated E. coli K1 invasion of BMECs and cytoskeletal rearrangements are
independent of FAK and PI3K, but dependent on RhoA.
To our knowledge, this is the first report describing the role of
CNF1 in the pathogenesis of meningitis due to E. coli K1. The cnf1 deletion mutant was significantly less invasive in
human BMECs in vitro as well as significantly less efficient
in penetration of the blood-brain barrier in the experimental
hematogenous E. coli meningitis animal model in
vivo compared with the parent E. coli K1 strain. We
have previously shown that a high degree of bacteremia is a primary
determinant for meningeal invasion by E. coli K1 (27);
however, the magnitude of bacteremia was similar between the two groups
of animals infected with the cnf1 deletion mutant or the
parent strain (Table I). These findings indicate that CNF1 is indeed a
critical determinant for E. coli K1 penetration of the
central nervous system in vivo. This finding is in contrast
to previous reports describing the inconsistent contribution of CNF1 to
uropathogenesis in vivo (28-30).
We have previously shown that FAK and PI3K are essential for E. coli K1 invasion of human BMECs (Table II) (9, 10). In addition,
we have shown that PI3K interacts with FAK in human BMECs and that its
interaction is increased in human BMECs stimulated with E. coli K1 (9, 10), suggesting that FAK recruits PI3K to the sites of
bacterial entry. PI3K activation is abolished in dominant-negative FAK
mutants (10), indicating that FAK is upstream of PI3K in E. coli K1 invasion of human BMECs. CNF1 has been shown to enhance
tyrosine phosphorylation of FAK and formation of stress fibers in Swiss
3T3 fibroblasts (31). In contrast, as shown in this study, increased
stress fiber formation and E. coli K1 invasion in response
to CNF1 in human BMECs were independent of FAK and PI3K. These findings
suggest that the requirement of FAK and PI3K for E. coli K1
invasion of human BMECs was overcome by CNF1 treatment of human BMECs.
We have previously shown that several determinants of E. coli K1 such as OmpA and Ibe proteins contribute to BMEC invasion
(2-7), and it is tempting to speculate that the contribution of
OmpA and Ibe proteins to E. coli K1 invasion of BMECs may
involve FAK and PI3K. Additional studies are needed to determine
microbial factors contributing to E. coli K1 invasion of
BMECs and also requiring FAK and PI3K activation.
One of the novel findings in this study is that E. coli K1
invasion of human BMECs was dependent on Rho GTPase. This was shown using dominant-negative RhoA-expressing BMECs as well as the Rho kinase
inhibitor Y-27632, both of which showed significant decreases in
E. coli K1 invasion of human BMECs. Of interest, the
cnf1 deletion mutant was significantly less efficient in
invasion of human BMECs as well as in RhoA activation compared with the
parent E. coli K1 strain, suggesting that CNF1 contributes
to E. coli K1 invasion of BMECs via RhoA activation. This
concept was further supported by the demonstration that the decreased
invasion observed with the cnf1 deletion mutant was restored
to the level of the parent E. coli K1 strain using BMECs
with constitutively active RhoA. Also, similar to the enhancing effects
of CNF1 on E. coli K1 invasion of BMECs, invasion assays
using BMECs with constitutively active RhoA resulted in significantly
increased invasion, suggesting that RhoA activation can substitute for
CNF1 in enhancing E. coli K1 invasion of BMECs. Taken
together, these findings suggest that CNF1 mediates E. coli
K1 invasion of BMECs via RhoA activation. Of interest, the enhancing
effects of constitutively active RhoA on E. coli K1 invasion
were not as high as those achieved using CNF1 (~8-fold
versus 40-fold increases, respectively). One explanation may
be the use of different methods of activating RhoA, i.e.
transfection versus CNF1 treatment. An alternative
explanation may be related to the concept that CNF1 may activate RhoA
and other Rho GTPases, resulting in greater E. coli K1
invasion of BMECs.
In their active GTP-bound form, Rho GTPases interact with many
effectors, including serine/threonine kinases, lipid kinases, and
several adaptor proteins (32-34), affecting the host cell actin cytoskeleton and leading to increased formation of stress fibers (14,
15, 18, 31). Several lines of evidence suggest that PI3K plays an
important role in host cell cytoskeletal remodeling and trafficking
(35). For example, PI3K controls Rho-mediated changes in the actin
cytoskeleton in fibroblasts (36, 37). We showed that CNF1 treatment
increased stress fiber formation in dominant-negative PI3K-expressing
BMECs, whereas this effect was minimal in dominant-negative
RhoA-expressing BMECs and in Y-27632-pretreated BMECs. In addition,
RhoA activation (as shown by GTP-RhoA) was shown to occur in response
to CNF1 in dominant-negative PI3K-expressing BMECs. Overall, these data
indicate that E. coli K1-induced stress fiber formation of
BMECs is dependent upon RhoA, FAK, and PI3K, but that CNF1 treatment is
able to overcome the requirement of FAK and PI3K, suggesting different
mechanisms for E. coli K1 and CNF1 for their abilities to
induce stress fiber formation and also to induce bacterial entry into
human BMECs.
We have previously documented that other meningitis-causing bacteria
such as group B Streptococcus (38) and
Citrobacter (39) are able to invade human BMECs by
inducing host cell actin cytoskeletal rearrangements, but the basis of
actin cytoskeletal rearrangements by these meningitis-causing bacteria
is unclear. In this study, we demonstrated that CNF1 contributes to
E. coli K1 invasion of BMECs by modulating actin
cytoskeletal rearrangements through activation of RhoA. More
importantly, we identified CNF1 as a critical determinant for E. coli K1 penetration of the central nervous system in
vivo. Our findings with CNF1-producing E. coli K1
illustrate that CNF1 in a whole bacterium is able to contribute to BMEC invasion in vitro and penetration into the central
nervous system in vivo. In contrast, previous reports
describing CNF1-mediated enhancement of bacterial invasion of host
cells have shown with addition of only exogenous CNF1 (14). Of
interest, CNF1 is considered to be a cytosolic protein and not to be
secreted from the whole bacterium. It remains unclear how CNF1 in the
whole bacterium is able to provide the BMEC invasion phenotype and RhoA
activation, and studies are in progress to address this issue.
We thank A. Hall and M. Schwartz for
providing dominant-negative RhoA (N19RhoA) and constitutively active
RhoA (V14RhoA) constructs.
*
This work was supported by National Institutes of Health
Grants NS 26310, AI 47225, and HL 61951.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Division of
Pediatric Infectious Diseases, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Park 256, Baltimore, MD 21287. Tel.: 410-614-3917; Fax: 410-614-1491; E-mail: kwangkim@jhmi.edu.
Published, JBC Papers in Press, February 27, 2002, DOI 10.1074/jbc.M112224200
The abbreviations used are:
BMECs, brain
microvascular endothelial cells;
FAK, focal adhesion kinase;
PI3K, phosphatidylinositol 3-kinase;
CNF1, cytotoxic necrotizing factor-1;
TRITC, tetramethylrhodamine isothiocyanate.
Cytotoxic Necrotizing Factor-1 Contributes to Escherichia
coli K1 Invasion of the Central Nervous System*
,
,
,
§¶
Division of Pediatric Infectious Diseases, Johns
Hopkins University School of Medicine, Baltimore, Maryland 21287
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
cnf1 mutant of E. coli
K1 and (b) restoration of invasion frequency of the
cnf1 mutant to the level of the parent E. coli K1 strain in BMECs with constitutively active RhoA. In
addition, CNF1-enhanced E. coli invasion of brain
endothelial cells and stress fiber formation were independent of focal
adhesion kinase and phosphatidylinositol 3-kinase activation. This is
the first demonstration that CNF1 contributes to E. coli K1
invasion of BMECs.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
pir (19) was used as the host for suicide plasmids. E. coli strains were routinely grown at 37 °C in Luria broth.
Where appropriate, the medium was supplemented with ampicillin (100 µg/ml), kanamycin (40 µg/ml), chloramphenicol (25 µg/ml), or
rifampin (50 µg/ml).
p110
(a kinase-negative catalytic subunit of PI3K) and
p85 (defective in
interaction with p110) were prepared as previously described (10). A
FAK mutant lacking the autophosphorylation site (Phe397FAK) was
prepared as described previously (9). Dominant-negative RhoA (N19RhoA, constructed by replacing threonine 19 with asparagine) and
constitutively active RhoA (V14RhoA, constructed by replacing glycine
14 with valine using oligonucleotide-directed mutagenesis) constructs were used as previously described (22, 23). All constructs were cloned
into the pCMV-based vector pcDNA3 (Invitrogen) and transfected into
human BMECs using LipofectAMINE (Invitrogen) as previously described
(10). Briefly, a DNA-LipofectAMINE complex in RPMI 1640 medium was
added to 50% confluent human BMEC monolayers. After 6 h of
incubation, cells were washed and grown in complete medium for 72 h, followed by selection with G418 (400 µg/ml). Antibiotic-resistant
colonies were pooled and confirmed by Western blotting.
-glycerophosphate, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100, 1 mM
Na3VO4, 50 mM NaF, 1 mM
phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin). Samples were centrifuged at 10,000 × g for 6 min at 4 °C, and the supernatant
was collected for protein quantification.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
cnf1) was generated (Fig. 1). The deletion of cnf1 in
the mutant strain was verified by PCR (data not shown) as well as by
Western blotting (Fig. 2). The growth
characteristics of strain E44 and the
cnf1 mutant were
identical on Luria broth and blood agar. In addition, the total
protein profiles as assessed by SDS-PAGE were identical for strain E44
and the
cnf1 mutant (data not shown). Both strain E44 and
the
cnf1 mutant were used for invasion assays. We
observed that the cnf1 deletion mutant was significantly
less invasive in BMECs compared with the parent strain (Fig.
3). To examine whether the
cnf1 deletion mutant is indeed less invasive in
vivo, the cnf1 mutant and the parent strain were
administered to 5-day-old rats. As shown in Table
I, subcutaneous injection of
105 colony-forming units of strain E44 or its
cnf1 mutant resulted in bacteremia in 100% of the animals,
and the magnitude of the bacteremia was similar between the two groups.
A total of 10 of 26 animals (38%) infected with strain E44 were found
to have meningitis. In contrast, only 3 of 28 animals (11%) developed
meningitis, and this rate of meningitis was significantly less
(p = 0.026) than the rate observed with the
cnf1 mutant. These findings indicate that CNF1 is a critical
determinant for E. coli K1 to invade human BMECs in
vitro and to cross the blood-brain barrier in vivo. It is also important to recognize that the frequency of in
vitro BMEC invasion (~0.1%) corresponds to the enhanced
bacterial penetration of the blood-brain barrier in vivo
(Fig. 3 and Table I) (2-4, 7).

View larger version (20K):
[in a new window]
Fig. 1.
Detailed map of the cnf1
deletion mutant. Shown is the organization of the
cnf1 deletion DNA compared with its parent strain (E44) and
plasmid pBluescript KS cloned with cnf1. Restriction sites
are as follows: E1, EcoRI; A,
AccI; Bg, BglII; Ev,
EcoRV; P, PstI; X,
XmnI.

View larger version (11K):
[in a new window]
Fig. 2.
Western blot showing CNF1 from strain E44,
its cnf1 deletion mutant, and strain JM101 containing
pBluescript KS cloned with cnf1. Bacterial strain
E44, its cnf1 deletion mutant, and strain JM101 containing
plasmid cloned with cnf1 were grown overnight. Total
bacterial lysates were electrophoresed on polyacrylamide gel,
transferred to nitrocellulose membrane, and Western-blotted using
anti-CNF1 polyclonal antibody. Note that the cnf1 deletion
mutant of strain E44 did not exhibit CNF1 expression.

View larger version (5K):
[in a new window]
Fig. 3.
The cnf1 deletion mutant of
E. coli K1 strain E44 (O18:K1:H7) exhibits decreased
invasion of human BMECs. To determine whether CNF1 plays a role in
the E44 invasion of BMECs, invasion assays were performed using the
cnf1 deletion mutant of strain E44 in human BMECs (25). A
significant decrease in the invasion of BMECs was observed with the
mutant compared with its parent strain. A noninvasive laboratory
E. coli strain (HB101) was used as a negative control.
Error bars indicate S.D. Data represent the average of three
independent experiments.
Comparison of number of animals with positive cerebrospinal fluid
cultures for E. coli between two groups of animals receiving E. coli K1
strain E44 or its cnf1 deletion mutant
RhoA) or BMECs with
constitutively active RhoA (RhoA). E. coli K1 invasion was decreased by >50% in human BMECs expressing dominant-negative RhoA
(Fig. 5 and Table
II), whereas BMECs with constitutively active RhoA exhibited a marked increase in E. coli K1
invasion of human BMECs (Fig. 5). Taken together, these findings
indicate that RhoA activation is required for efficient E. coli K1 invasion of human BMECs.

View larger version (8K):
[in a new window]
Fig. 4.
The Rho kinase inhibitor Y-27632 blocks
E. coli K1 invasion of human BMECs. E. coli invasion assays were performed with human BMECs treated with
the Rho kinase inhibitor Y-27632 at different concentrations for 30 min. Control invasion assays were performed without prior Y-27632
treatment. Note that Y-27632 (Y) at both 10 and 50 µM significantly decreased E. coli K1 invasion
of human BMECs (p < 0.05, calculated using an unpaired
t test with Slide Write Plus Version 3 for Windows).
Experiments were performed in triplicates. Error bars
represent S.D.

View larger version (7K):
[in a new window]
Fig. 5.
Expression of dominant-negative RhoA
decreases BMEC invasion by E. coli K1 strain E44,
whereas expression of constitutively active RhoA increases BMEC
invasion by strain E44 as well as by its cnf1 deletion
mutant. Human BMECs were transfected with pcDNA3 cloned with
dominant-negative RhoA (N19RhoA) or constitutively active RhoA
(V14RhoA) as described under "Experimental Procedures." As
controls, cells were transfected with pcDNA3 alone. Invasion assays
were performed using E. coli K1 strain E44 or its
cnf1 deletion mutant. Note that E44 invasion was decreased
in dominant-negative RhoA-expressing BMECs, whereas the cnf1
deletion mutant was able to invade human BMECs exhibiting
constitutively active RhoA to the level of parent strain E44.
CNF1 increases E. coli K1 invasion in pcDNA-transfected BMECs as
well as in dominant-negative FAK- and PI3K-expressing BMECs, but not in
dominant-negative RhoA-expressing BMECs or in the presence of the Rho
kinase inhibitor Y-27632

View larger version (12K):
[in a new window]
Fig. 6.
The cnf1 deletion mutant of
E. coli K1 strain E44 (O18:K1:H7) exhibits decreased
RhoA activation. a, RhoA activation (GTP-RhoA) was
significantly reduced with the cnf1 deletion mutant compared
with parent strain E44 (p < 0.05, calculated from the
density of the bands using an unpaired t test with Slide
Write Plus Version 3 for Windows). Control indicates BMECs
treated with HB101. Human BMECs were treated with E44 and its
cnf1 deletion mutant, and GTP-RhoA was collected as
described under "Experimental Procedures." Western blotting was
performed using anti-RhoA antibody (26). Before performing glutathione
S-transferase-rhotekin incubation, an aliquot of each sample
was analyzed by Western blotting using anti-RhoA antibody, showing
equal amounts of proteins in all samples. b, quantitation of
the GTP-RhoA bands in a was performed. The density of the
GTP-RhoA bands was quantitated using an imaging densitometer. Data
represent the average of three independent experiments. Error
bars indicate S.D.

View larger version (106K):
[in a new window]
Fig. 7.
CNF1-mediated stress fiber formation is
dependent on RhoA. CNF1 was incubated with BMECs transfected with
pcDNA3 alone or with pcDNA3 encoding dominant-negative RhoA,
FAK, and PI3K. BMECs were fixed and stained with anti-actin antibody
and visualized under immunofluorescence. Note that CNF1 increased
stress fiber formation in both dominant-negative FAK- and
PI3K-expressing BMECs, but not in dominant-negative RhoA-expressing
cells. Data represent the average of three independent
experiments.

View larger version (37K):
[in a new window]
Fig. 8.
CNF1 activation of RhoA is independent of
PI3K and FAK. a, BMECs expressing pcDNA3 or
dominant-negative RhoA, PI3K, or FAK were treated with CNF1 for 30 min,
and GTP-RhoA was collected as described under "Experimental
Procedures." b, quantitation of the GTP-RhoA bands in
a was carried out. Data represent the average of three
independent experiments. Error bars indicate S.D.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Kim, K. S.
(2000)
Subcell. Biochem.
33,
47-59[Medline]
[Order article via Infotrieve] 2.
Badger, J. L.,
Wass, C. A.,
Weissman, S. J.,
and Kim, K. S.
(2000)
Infect. Immun.
68,
5056-5061 3.
Hoffman, J. A.,
Badger, J. L.,
Zhang, Y.,
Huang, S. H.,
and Kim, K. S.
(2000)
Infect. Immun.
68,
5062-5067 4.
Huang, S. H.,
Chen, Y. H., Fu, Q.,
Stins, M.,
Wang, Y.,
Wass, C.,
and Kim, K. S.
(1999)
Infect. Immun.
67,
2103-2109 5.
Prasadarao, N. V.,
Wass, C. A.,
Weiser, J. N.,
Stins, M. F.,
Huang, S. H.,
and Kim, K. S.
(1996)
Infect. Immun.
64,
146-153[Abstract] 6.
Prasadarao, N. V.,
Wass, C. A.,
Huang, S. H.,
and Kim, K. S.
(1999)
Infect. Immun.
67,
1131-1138 7.
Wang, Y.,
Huang, S. H.,
Wass, C. A.,
Stins, M. F.,
and Kim, K. S.
(1999)
Infect. Immun.
67,
4751-4756 8.
Prasadarao, N. V.,
Wass, C. A.,
Stins, M. F.,
Shimada, H.,
and Kim, K. S.
(1999)
Infect. Immun.
67,
5775-5783 9.
Reddy, M. A.,
Wass, C. A.,
Kim, K. S.,
Schlaepfer, D. D.,
and Prasadarao, N. V.
(2000)
Infect. Immun.
68,
6423-6430 10.
Reddy, M. A.,
Prasadarao, N. V.,
Wass, C. A.,
and Kim, K. S.
(2000)
J. Biol. Chem.
275,
36769-36774 11.
Caprioli, A.,
Falbo, V.,
Ruggeri, F. M.,
Baldassarri, L.,
Bisicchia, R.,
Ippolito, G.,
Romoli, E.,
and Donelli, G.
(1987)
J. Clin. Microbiol.
25,
146-149 12.
Falbo, V.,
Famiglietti, M.,
and Caprioli, A.
(1992)
Infect. Immun.
60,
2182-2187 13.
Caprioli, A.,
Falbo, V.,
Roda, L. G.,
Ruggen, F. M.,
and Zona, C.
(1983)
Infect. Immun.
39,
1300-1306 14.
Falzano, L.,
Fiorentini, C.,
Donelli, G.,
Michel, E.,
Kocks, C.,
Cossart, P.,
Cabanie, L.,
Oswald, E.,
and Boquet, P.
(1993)
Mol. Microbiol.
9,
1247-1254[Medline]
[Order article via Infotrieve] 15.
Fiorentini, C.,
Fabbri, A.,
Matarrese, P.,
and Falzano, L.
(1998)
Biochem. Biophys. Res. Commun.
241,
341-346 16.
Flatau, G.,
Lemichez, E.,
Gauthier, M.,
Chardin, P.,
Paris, S.,
Fiorentini, C.,
and Boquet, P.
(1997)
Nature
387,
729-733[CrossRef][Medline]
[Order article via Infotrieve] 17.
Schmidt, G.,
Sehr, P.,
Wilm, M.,
Selzer, J.,
Mann, M.,
and Aktories, K.
(1997)
Nature
387,
725-729[CrossRef][Medline]
[Order article via Infotrieve] 18.
Vouret-Craviari, V.,
Grall, D.,
Flatau, G.,
Pouyssegur, J.,
Boquet, P.,
and Van Obberghen-Schilling, E.
(1999)
Infect. Immun.
67,
3002-3008 19.
Taylor, R. K.,
Manoil, C.,
and Mekalanos, J. J.
(1989)
J. Bacteriol.
171,
1870-1878 20.
Falbo, V.,
Pace, T.,
Picci, L.,
Pizzi, E.,
and Caprioli, A.
(1993)
Infect. Immun.
61,
4909-4914 21.
Stins, M. F.,
Gilles, F.,
and Kim, K. S.
(1997)
J. Neuroimmunol.
76,
81-90[CrossRef][Medline]
[Order article via Infotrieve] 22.
Khosravi-Far, R.,
Solski, P. A.,
Clark, G. J.,
Kinch, M. S.,
and Der, C. J.
(1995)
Mol. Cell. Biol.
15,
6443-6453[Abstract] 23.
Tzima, E.,
Del Pozo, M. A.,
Shattil, S. J.,
Chien, S.,
and Schwartz, M. A.
(2001)
EMBO J.
20,
4639-4647[CrossRef][Medline]
[Order article via Infotrieve] 24.
Bodie, S. L.,
Ford, I.,
Greaves, M.,
and Nixon, G. F.
(2001)
Biochem. Biophys. Res. Commun.
287,
71-76[CrossRef][Medline]
[Order article via Infotrieve] 25.
Huang, S. H.,
Wass, C., Fu, Q.,
Prasadarao, N. V.,
Stins, M.,
and Kim, K. S.
(1995)
Infect. Immun.
63,
4470-4475[Abstract] 26.
Jin, S.,
and Exton, J. H.
(2000)
Biochem. Biophys. Res. Commun.
277,
718-721[CrossRef][Medline]
[Order article via Infotrieve] 27.
Kim, K. S.,
Itabashi, H.,
Gemski, P.,
Sadoff, J.,
Warren, R. L.,
and Cross, A. S.
(1992)
J. Clin. Invest.
90,
897-905[Medline]
[Order article via Infotrieve] 28.
Fournout, S.,
Dozois, C. M.,
Odin, M.,
Desautels, C.,
Peres, S.,
Herault, F.,
Daigle, F.,
Segafredo, C.,
Laffitte, J.,
Oswald, E.,
Fairbrother, J. M.,
and Oswald, I. P.
(2000)
Infect. Immun.
68,
839-847 29.
Rippere-Lampe, K. E.,
O'Brien, A. D.,
Conran, R.,
and Lockman, H. A.
(2001)
Infect. Immun.
69,
3954-3964 30.
Johnson, D. E.,
Drachenberg, C.,
Lockatell, C. V.,
Island, M. D.,
Warren, J. W.,
and Donnenberg, M. S.
(2000)
FEMS Immunol. Med. Microbiol.
28,
37-41[CrossRef][Medline]
[Order article via Infotrieve] 31.
Lacerda, H. M.,
Pullinger, G. D.,
Lax, A. J.,
and Rozengurt, E.
(1997)
J. Biol. Chem.
272,
9587-9596 32.
Hall, A.
(1998)
Science
279,
509-514 33.
Maekawa, M.,
Ishizaki, T.,
Boku, S.,
Watanabe, N.,
Fujita, A.,
Iwamatsu, A.,
Obinata, T.,
Ohashi, K.,
Mizuno, K.,
and Narumiya, S.
(1999)
Science
285,
895-898 34.
Matsui, T.,
Maeda, M.,
Doi, Y.,
Yonemura, S.,
Amano, M.,
Kaibuchi, K.,
Tsukita, S.,
and Tsukita, S.
(1998)
J. Cell Biol.
140,
647-657 35.
Wymann, M. P.,
and Pirola, L.
(1998)
Biochim. Biophys. Acta
1436,
127-150[Medline]
[Order article via Infotrieve] 36.
Reif, K.,
Nobes, C. D.,
Thomas, G.,
Hall, A.,
and Cantrell, D. A.
(1996)
Curr. Biol.
6,
1445-1455[CrossRef][Medline]
[Order article via Infotrieve] 37.
Cantrell, D. A.
(2001)
J. Cell Sci.
114,
1439-1445[Abstract] 38.
Nizet, V.,
Kim, K. S.,
Stins, M.,
Jonas, M.,
Chi, E. Y.,
Nguyen, D.,
and Rubens, C. E.
(1997)
Infect. Immun.
65,
5074-5081[Abstract] 39.
Badger, J. L.,
Stins, M. F.,
and Kim, K. S.
(1999)
Infect. Immun.
67,
4208-4215
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
R. Mittal and N. V. Prasadarao Outer Membrane Protein A Expression in Escherichia coli K1 Is Required to Prevent the Maturation of Myeloid Dendritic Cells and the Induction of IL-10 and TGF-{beta} J. Immunol., August 15, 2008; 181(4): 2672 - 2682. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Fagan, M. A. Lambert, and S. G. J. Smith The Hek Outer Membrane Protein of Escherichia coli Strain RS218 Binds to Proteoglycan and Utilizes a Single Extracellular Loop for Adherence, Invasion, and Autoaggregation Infect. Immun., March 1, 2008; 76(3): 1135 - 1142. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mokri-Moayyed, G. J. Goldsworthy, and N. A. Khan Development of a novel ex vivo insect model for studying virulence determinants of Escherichia coli K1 J. Med. Microbiol., January 1, 2008; 57(1): 106 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Khan and G. J. Goldsworthy Novel Model To Study Virulence Determinants of Escherichia coli K1 Infect. Immun., December 1, 2007; 75(12): 5735 - 5739. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Parthasarathy, Y. Yao, and K. S. Kim Flagella Promote Escherichia coli K1 Association with and Invasion of Human Brain Microvascular Endothelial Cells Infect. Immun., June 1, 2007; 75(6): 2937 - 2945. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Teng, Y. Xie, S. Shin, F. Di Cello, M. Paul-Satyaseela, M. Cai, and K. S. Kim Effects of ompA Deletion on Expression of Type 1 Fimbriae in Escherichia coli K1 Strain RS218 and on the Association of E. coli with Human Brain Microvascular Endothelial Cells. Infect. Immun., October 1, 2006; 74(10): 5609 - 5616. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Alsam, S. R. Jeong, J. Sissons, R. Dudley, K. S. Kim, and N. A. Khan Escherichia coli interactions with Acanthamoeba: a symbiosis with environmental and clinical implications J. Med. Microbiol., June 1, 2006; 55(6): 689 - 694. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yao, Y. Xie, and K. S. Kim Genomic Comparison of Escherichia coli K1 Strains Isolated from the Cerebrospinal Fluid of Patients with Meningitis Infect. Immun., April 1, 2006; 74(4): 2196 - 2206. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sissons, K. S. Kim, M. Stins, S. Jayasekera, S. Alsam, and N. A. Khan Acanthamoeba castellanii Induces Host Cell Death via a Phosphatidylinositol 3-Kinase-Dependent Mechanism Infect. Immun., May 1, 2005; 73(5): 2704 - 2708. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Korczak, J. Frey, J. Schrenzel, G. Pluschke, R. Pfister, R. Ehricht, and P. Kuhnert Use of Diagnostic Microarrays for Determination of Virulence Gene Patterns of Escherichia coli K1, a Major Cause of Neonatal Meningitis J. Clin. Microbiol., March 1, 2005; 43(3): 1024 - 1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Kim, J. W. Chung, and K. S. Kim 67-kDa Laminin Receptor Promotes Internalization of Cytotoxic Necrotizing Factor 1-expressing Escherichia coli K1 into Human Brain Microvascular Endothelial Cells J. Biol. Chem., January 14, 2005; 280(2): 1360 - 1368. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Munro, G. Flatau, A. Doye, L. Boyer, O. Oregioni, J.-L. Mege, L. Landraud, and E. Lemichez Activation and Proteasomal Degradation of Rho GTPases by Cytotoxic Necrotizing Factor-1 Elicit a Controlled Inflammatory Response J. Biol. Chem., August 20, 2004; 279(34): 35849 - 35857. [Abstract] [Full Text] [PDF] |
||||
![]() |